Novel Approaches to Target MECOM/EVI1 in AML

Gruppo Italiano Malattie EMatologiche dell'Adulto

Status: Enrolling

Conditions: AML, Adult

Treatments: Biological: Biological characterization of AML with MECOM or atypical 3q26 rearrangements

Study type: Interventional

Funder types: Other

Identifiers

NCT05839392

AML2623

Details and patient eligibility

About

This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements.

Full description

This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements. To this end, BM samples and formalin fixed/paraffin-embedded BM biopsies will be collected at enrolment, before and after treatment, at relapse.

Enrollment: 24 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• AML with MECOM or atypical 3q26 rearrangements.
• Age ≥18.
• Signed written informed consent according to ICH/EU/GCP and national local laws.

Exclusion criteria

• None

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)